{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:52:13Z","timestamp":1790009533323,"version":"4.0.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"crossref","award":["ZR2021MH256"],"award-info":[{"award-number":["ZR2021MH256"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81573778"],"award-info":[{"award-number":["81573778"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To evaluate the effect of basal luteinizing hormone (bLH) levels on In Vitro Fertilization\/Intra-Cytoplasmic Injections (IVF\/ICSI) outcomes in polycystic ovary syndrome (PCOS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 256 PCOS patients who underwent IVF\/ICSI treatment in our center from January 2018 to January 2022 were analyzed retrospectively. The patients were based on the third quartile (12.455) of the basal LH value was taken as the cut-off value and was divided into high and low LH group: high LH group (LH\u2009\u2265\u200912.455 IU \/ L) and low LH group (LH\u2009&lt;\u200912.455 IU \/ L) and the OC group was pretreated with oral contraceptives. The outcomes in ovulation induction and embryo transfer cycles of the three groups were then compared. In addition, factors influencing the number of good quality embryos and the early onset LH peak were analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Ages, infertility duration, body mass index (BMI), and basal follicle-stimulating hormone (FSH), and progesterone (P), testosterone (T) levels were not significantly different among the three groups (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). However,there were significant differences in basal LH and basal E2 between low LH group and high LH group, and there were significant differences in basal LH between high LH group and OC group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). LH on the antagonist day was significantly different between low LH group and high LH group and between high LH group and OC group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). LH on the hCG (human Chorionic Gonadotropin) day there were significant differences between low LH group and OC group, high LH group and OC group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). The Mode of triggering between the three groups had significant differences between the two groups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). In addition, the number of days from gonadotropin (Gn) initiation to antagonist addition were significantly different among the three groups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). In addition, total Gn doses,the number of oocytes retrieved, the number of Gn days, 2pronucleus (2PN) numbers, number of good quality embryos, and number of high risk OHSS (Ovarian Hyper-stimulation Syndrome), cases with OHSS occurrences were not significantly different among the three groups (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). Moreover, the cycle and clinical pregnancy outcomes and the cumulative clinical pregnancy rate and the cumulative live birth rate were not significantly different among the three groups (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). LH levels on the day of antagonist addition affected the number of good-quality embryos (B\u2009&lt;\u20090, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). However, LH levels on the day antagonist was added were not significantly correlated with basal LH levels (Pearson correlation coefficient\u2009=\u20090.259), the ROC curve was constructed for the logistic prediction model of the early onset LH peak, and the AUC value was 0.747, indicating that the logistic combined model we constructed had a good ability to predict the early onset LH peak.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Basal LH levels do not affect the pregnancy outcomes in PCOS patients after antagonist protocols. Besides, LH levels on the day of antagonist addition affect the number of good quality embryos for PCOS patients undergoing IVF \/ICSI.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12884-023-05944-4","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T13:03:04Z","timestamp":1693314184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effect of basal luteinizing hormone (bLH) level on in vitro fertilization\/intra-cytoplasmic injections (IVF\/ICSI) outcomes in polycystic ovarian syndrome (PCOS) patients"],"prefix":"10.1186","volume":"23","author":[{"given":"Zhuo","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"issue":"3","key":"5944_CR1","doi-asserted-by":"publisher","first-page":"e1071","DOI":"10.1210\/clinem\/dgaa839","volume":"106","author":"A HOEGER K M, DOKRAS","year":"2021","unstructured":"HOEGER K M, DOKRAS A, PILTONEN T. Update on PCOS:Consequences,Challenges,and Guiding treatment. J Clin Endocrinol Metab. 2021;106(3):e1071\u2013e83.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"5944_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4103\/jhrs.JHRS_95_18","volume":"13","author":"R DESWAL","year":"2020","unstructured":"DESWAL R, NARWAL V. The prevalence of polycystic ovary syndrome:a brief systematic review. J Hum Reproductive Sci. 2020;13(4):261\u201371.","journal-title":"J Hum Reproductive Sci"},{"key":"5944_CR3","doi-asserted-by":"publisher","unstructured":"Hu C, Pang B, Ma Z, Yi H. Immunophenotypic profiles in polycystic ovary Syndrome. Mediators Inflamm. 2020;2020:5894768. Published 2020 Mar 19. https:\/\/doi.org\/10.1155\/2020\/5894768.","DOI":"10.1155\/2020\/5894768"},{"key":"5944_CR4","doi-asserted-by":"crossref","unstructured":"BRUNI V,CAPOZZI A LELLOS. The role of Genetics, Epigenetics and Lifestyle in Polycystic Ovary Syndrome Development:the state of the art. Reprod Sci (Thousand Oaks,Calif), 2022, 29(3):668\u201379.","DOI":"10.1007\/s43032-021-00515-4"},{"key":"5944_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.coemr.2020.07.004","volume":"14","author":"SF Witchel","year":"2020","unstructured":"Witchel SF, Plant TM. Intertwined reproductive endocrinology: Puberty and polycystic ovary syndrome.Curr Opin. Endocr Metab Res. 2020;14:127\u201336. https:\/\/doi.org\/10.1016\/j.coemr.2020.07.004.","journal-title":"Endocr Metab Res"},{"issue":"11","key":"5944_CR6","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1042\/CS20220146","volume":"137","author":"K Koysombat","year":"2023","unstructured":"Koysombat K, Dhillo WS, Abbara A. Assessing hypothalamic pituitary gonadal function in reproductive disorders. Clin Sci (Lond). 2023;137(11):863\u201379. https:\/\/doi.org\/10.1042\/CS20220146.","journal-title":"Clin Sci (Lond)"},{"key":"5944_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/bs.acc.2019.11.004","volume":"96","author":"IR Ilie","year":"2020","unstructured":"Ilie IR. Neurotransmitter, neuropeptide and gut peptide profile in PCOS-pathways contributing to the pathophysiology,food intake and psychiatric manifestations of PCOS. Adv Clin Chem. 2020;96:85\u2013135. https:\/\/doi.org\/10.1016\/bs.acc.2019.11.004.","journal-title":"Adv Clin Chem"},{"issue":"2","key":"5944_CR8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/09513590.2018.1500535","volume":"35","author":"Z Xu","year":"2019","unstructured":"Xu Z, Meng L, Pan C, Chen X, Huang X, Yang H. Does oral contraceptives pretreatment affect the pregnancy outcome in polycystic ovary syndrome women undergoing ART with GnRH agonist protocol? Gynecol Endocrinol. 2019;35(2):124\u20137. https:\/\/doi.org\/10.1080\/09513590.2018.1500535.","journal-title":"Gynecol Endocrinol"},{"key":"5944_CR9","doi-asserted-by":"publisher","unstructured":"Lu Y, Niu Y, Wang Y et al. Optimal Candidates to Do Fresh Embryo Transfer in Those Using Oral Contraceptive Pretreatment in IVF Cycles. Front Physiol. 2021;12:576917. Published 2021 Mar 11. https:\/\/doi.org\/10.3389\/fphys.2021.576917.","DOI":"10.3389\/fphys.2021.576917"},{"issue":"3","key":"5944_CR10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/ajo.13672","volume":"63","author":"C Thomas","year":"2023","unstructured":"Thomas C, Braund R, Bowden N, Hobbs M, Kokaua J, Paterson H. Disparities in utilisation of combined oral contraceptives in Aotearoa New Zealand: a cross-sectional whole-of-population study.Aust N. Z J Obstet Gynaecol. 2023;63(3):441\u20137. https:\/\/doi.org\/10.1111\/ajo.13672.","journal-title":"Z J Obstet Gynaecol"},{"key":"5944_CR11","unstructured":"Ma Wenhong W, Lihong Y, Chunling et al. Effect of oral contraceptive pretreatment and basal LH level on ivf\/icsi outcome in patients with polycystic ovary syndrome\u2013a prospective cohort study China prescription drugs, 2021,19 (08):7\u201310."},{"issue":"5","key":"5944_CR12","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s00404-020-05696-y","volume":"302","author":"MV De Diego","year":"2020","unstructured":"De Diego MV, G\u00f3mez-Pardo O, Groar JK, et al. Metabolic impact of current therapeutic strategies in polycystic ovary syndrome:a preliminary study. Arch Gynecol Obstet. 2020;302(5):1169\u201379. https:\/\/doi.org\/10.1007\/s00404-020-05696-y.","journal-title":"Arch Gynecol Obstet"},{"key":"5944_CR13","doi-asserted-by":"crossref","unstructured":"Song SY, Yang JB,Song MS et al. Effect of pretreatment withcombined oral contraceptives on outcomes of assisted reproduc-tive technology for women with polycystic ovary syndrome: a me-ta-analysis. Arch Gynecol Obstet ,2019,300 (3):737 \u2013 50.","DOI":"10.1007\/s00404-019-05210-z"},{"issue":"2","key":"5944_CR14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/09513590.2018.1500535","volume":"35","author":"ZMengL Xu","year":"2019","unstructured":"Xu ZMengL, Pan C, et al. Does oral contraceptives pretreat-ment affect the pregnancy outcome in polycystic ovary syndrome women undergoing ART with GnRH agonist protocol. J Gynaecol Endocrinol, 2019;35(2):124\u20137.","journal-title":"Gyne-cological Endocrinology:The Official Journal of the International Society of Gynecological Endocrinology"},{"issue":"2","key":"5944_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/humrep\/deac258","volume":"38","author":"I Homminga","year":"2023","unstructured":"Homminga I, Ter Meer AF, Groen H, Cantineau AEP, Hoek A. Thin endometrial lining: is it more prevalent in patients utilizing preimplantation genetic testing for monogenic disease (PGT-M) and related to prior hormonal contraceptive use? Hum Reprod. 2023;38(2):237\u201346. https:\/\/doi.org\/10.1093\/humrep\/deac258.","journal-title":"Hum Reprod"},{"issue":"1","key":"5944_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13048-023-01219-w","volume":"16","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Xu Y, Yu J, et al. A premature luteinizing hormone surge without elevated progesterone levels has no adverse effect on cumulative live birth rate in patient undergoing a flexible GnRH antagonist protocol: a retrospective study. J Ovarian Res. 2023;16(1):119. https:\/\/doi.org\/10.1186\/s13048-023-01219-w. Published 2023 Jun 27.","journal-title":"J Ovarian Res"},{"key":"5944_CR17","doi-asserted-by":"crossref","unstructured":"ZHANG, D,SUN, Z et al. The effect of a transient premature luteinizing hormone surge without elevated serum progesterone on in vitro fertilization outcomes in a gonadotropin-releasing hormone antagonist flexible protocol. J Gynaecol Endocrinol,2020,36(6):550\u20133.","DOI":"10.1080\/09513590.2019.1683730"},{"key":"5944_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/ijgo.12485","volume":"142","author":"YD Geng","year":"2018","unstructured":"Geng YD, Lai QH,Xun Y, et al. The effect of premature luteinizing hormone increases among high ovarian responders undergoing a gonadotropin-releasing hormone antagonist ovarian stimulation protocol. Int J Gynaecol Obstet. 2018;142:97\u2013103.","journal-title":"Int J Gynaecol Obstet"},{"issue":"16","key":"5944_CR19","doi-asserted-by":"publisher","first-page":"4670","DOI":"10.3390\/jcm11164670","volume":"11","author":"J Wang","year":"2022","unstructured":"Wang J, Ding J, Qu B, Zhang Y, Zhou Q, Does Serum LH. Level influence IVF outcomes in women with PCOS undergoing GnRH-Antagonist stimulation: a Novel Indicator. J Clin Med. 2022;11(16):4670. https:\/\/doi.org\/10.3390\/jcm11164670. Published 2022 Aug 11.","journal-title":"J Clin Med"},{"key":"5944_CR20","doi-asserted-by":"crossref","unstructured":"Rotterdlan ESHRE\/, ASRM-Sponsored PCOSconsensus workshop group. .Revised 2003 consensus on dliagnostic criteria and long-term health risks related to polyevstic ovarian syndrome (PCOS). Hum Reprod (Oxford, England), 2004.19(1):41\u20137.","DOI":"10.1093\/humrep\/deh098"},{"issue":"1","key":"5944_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/cen.14895","volume":"99","author":"L Wu","year":"2023","unstructured":"Wu L, Liu Y, Huang X, et al. Oral contraceptives (OCs) in combination with metformin versus OCs alone on metabolism in nonobese polycystic ovary syndrome: a meta-analysis and systematic review of randomized controlled trials. Clin Endocrinol (Oxf). 2023;99(1):3\u201316. https:\/\/doi.org\/10.1111\/cen.14895.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"5944_CR22","unstructured":"Xian Yexing H, Yan, Guo Xinyu. Research progress of empty follicle syndrome. Chin J Eugenics Genet 2022,30(10):1893\u20138."},{"key":"5944_CR23","doi-asserted-by":"publisher","first-page":"1106276","DOI":"10.3389\/fendo.2023.1106276","volume":"14","author":"R Gao","year":"2023","unstructured":"Gao R, Qin L, Li Z, Min W. The homeostasis model assessment of insulin resistance is a judgment criterion for metformin pre-treatment before IVF\/ICSI and embryo transfer cycles in patients with polycystic ovarian syndrome. Front Endocrinol (Lausanne). 2023;14:1106276. https:\/\/doi.org\/10.3389\/fendo.2023.1106276. Published 2023 Feb 9.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"5944_CR24","doi-asserted-by":"publisher","first-page":"830567","DOI":"10.3389\/fendo.2022.830567","volume":"13","author":"X Luo","year":"2022","unstructured":"Luo X, Li L, Lin N, Ma R, Li Y, Wu Z. Low endogenous LH on the COS initiation day of a GnRH-Agonist regimen increases the risk of early pregnancy loss and adverse ART Outcomes. Front endocrinol. (Lausanne). 2022;13:830567. https:\/\/doi.org\/10.3389\/fendo.2022.830567. Published 2022 Feb 21.","journal-title":"(Lausanne)"},{"issue":"01","key":"5944_CR25","first-page":"6","volume":"31","author":"X Shan","year":"2022","unstructured":"Shan X, Meilan M. The effect of early-onset LH elevation on the clinical outcome of IVF-ET in patients with polycystic ovary syndrome in the antagonist regimen. J Reprod Med. 2022;31(01):6\u201312.","journal-title":"J Reprod Med"},{"key":"5944_CR26","doi-asserted-by":"publisher","first-page":"640047","DOI":"10.3389\/fendo.2021.640047","volume":"12","author":"Y Luo","year":"2021","unstructured":"Luo Y, Liu S, Su H, et al. Low serum LH levels during ovarian stimulation with GnRH antagonist protocol decrease the live birth rate after fresh embryo transfers but have no impact in freeze-all cycles. Front Endocrinol (Lausanne). 2021;12:640047. https:\/\/doi.org\/10.3389\/fendo.2021.640047. Published 2021 Apr 23.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"5944_CR27","doi-asserted-by":"publisher","unstructured":"Luo X, Deng B, Li L, Ma R, Mai X, Wu Z. LH level on ovulation trigger day has a different impact on the outcomes of agonist and antagonist regimens during in vitro fertilization. J Ovarian Res. 2023;16(1):26. Published 2023 Jan 27. https:\/\/doi.org\/10.1186\/s13048-023-01110-8.","DOI":"10.1186\/s13048-023-01110-8"},{"issue":"1","key":"5944_CR28","first-page":"654","volume":"23","author":"S Liu","year":"2022","unstructured":"Liu S, Lv YS,Han S, et al. A novel GnRH antagonist protocol based on LH levels versus traditional flexible GnRH antagonist protocol in PCOS patients undergoing in vitro fertilization: study protocol for a randomized controlled. non-inferiority Trial Trials. 2022;23(1):654.","journal-title":"non-inferiority Trial Trials"},{"issue":"1","key":"5944_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4103\/jhrs.JHRS_96_20","volume":"14","author":"N Singh","year":"2021","unstructured":"Singh N, Mishra N, Dogra Y. Do basal luteinizing hormone and luteinizing hormone\/follicle-stimulating hormone ratio have significance in prognosticating the outcome of in vitro fertilization cycles in polycystic ovary syndrome? J Hum Reprod Sci. 2021;14(1):21\u20137.","journal-title":"J Hum Reprod Sci"},{"issue":"5","key":"5944_CR30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/OGX.0000000000001133","volume":"78","author":"S Giouleka","year":"2023","unstructured":"Giouleka S, Tsakiridis I, Arsenaki E, et al. Investigation and management of recurrent pregnancy loss: a Comprehensive Review of Guidelines. Obstet Gynecol Surv. 2023;78(5):287\u2013301.","journal-title":"Obstet Gynecol Surv"},{"issue":"1","key":"5944_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00404-023-07001-z","volume":"308","author":"C Ticconi","year":"2023","unstructured":"Ticconi C, Nicastri E, D\u2019Ippolito S, et al. Diagnostic factors for recurrent pregnancy loss: an expanded workup. Arch Gynecol Obstet. 2023;308(1):127\u201342. https:\/\/doi.org\/10.1007\/s00404-023-07001-z.","journal-title":"Arch Gynecol Obstet"},{"key":"5944_CR32","doi-asserted-by":"publisher","first-page":"592495","DOI":"10.3389\/fendo.2020.592495","volume":"11","author":"YF Sun","year":"2020","unstructured":"Sun YF, Zhang J, Xu YM, et al. High BMI and insulin resistance are risk factors for spontaneous abortion in patients with polycystic ovary syndrome undergoing assisted Reproductive Treatment:a systematic review and Meta-analysis. Front Endocrinol (Lausanne). 2020;11:592495.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"5944_CR33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1056\/NEJMoa1705334","volume":"378","author":"Y Shi","year":"2018","unstructured":"Shi Y, Sun Y, Hao C, Zhang H, Wei D, Zhang Y, Zhu Y, Deng X, Qi X, Li H, et al. Transfer of fresh versus frozen embryos in ovulatory women. N Engl J Med. 2018;378(2):126\u201336.","journal-title":"N Engl J Med"},{"issue":"2","key":"5944_CR34","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa1703768","volume":"378","author":"LN Vuong","year":"2018","unstructured":"Vuong LN, Dang VQ, Ho TM, et al. IVF transfer of fresh or frozen embryos in women without polycystic Ovaries. N Engl. J Med. 2018;378(2):137\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1703768.","journal-title":"J Med"},{"issue":"2","key":"5944_CR35","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.xfre.2022.12.003","volume":"4","author":"KE Kostroun","year":"2022","unstructured":"Kostroun KE, Goldrick K, Mondshine JN, et al. Impact of updated international diagnostic criteria for the diagnosis of polycystic ovary syndrome.F. S Rep. 2022;4(2):173\u20138. https:\/\/doi.org\/10.1016\/j.xfre.2022.12.003. Published 2022 Dec 22.","journal-title":"S Rep"},{"key":"5944_CR36","doi-asserted-by":"publisher","unstructured":"Yadav V, Sharma Y. Hyperandrogenism [published online ahead of print, 2023 Jul 4]. Indian J Pediatr. 2023;https:\/\/doi.org\/10.1007\/s12098-023-04678-7. doi:10.1007\/s12098-023-04678-7.","DOI":"10.1007\/s12098-023-04678-7"},{"issue":"1","key":"5944_CR37","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s40001-023-01174-8","volume":"28","author":"H Jiang","year":"2023","unstructured":"Jiang H, Si M, Tian T, et al. Adiposity and lipid metabolism indicators mediate the adverse effect of glucose metabolism indicators on oogenesis and embryogenesis in PCOS women undergoing IVF\/ICSI cycles. Eur J Med Res. 2023;28(1):216. https:\/\/doi.org\/10.1186\/s40001-023-01174-8. Published 2023 Jul 3.","journal-title":"Eur J Med Res"},{"key":"5944_CR38","doi-asserted-by":"publisher","unstructured":"Zhou X, Wang Y, Chen W et al. Circulating HHIP Levels in Women with Insulin Resistance and PCOS: Effects of Physical Activity, Cold Stimulation and Anti-Diabetic Drug Therapy. J Clin Med. 2023;12(3):888. Published 2023 Jan 22. https:\/\/doi.org\/10.3390\/jcm12030888.","DOI":"10.3390\/jcm12030888"},{"issue":"3","key":"5944_CR39","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s43032-021-00515-4","volume":"29","author":"V Bruni","year":"2022","unstructured":"Bruni V, et al. The role of Genetics, Epigenetics and Lifestyle in Polycystic Ovary Syndrome Development: the state of the Art. Reprod Sci (Thousand Oaks Calif)vol. 2022;29(3):668\u201379.","journal-title":"(Thousand Oaks Calif)vol"},{"issue":"2","key":"5944_CR40","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40618-020-01351-0","volume":"44","author":"P Moghetti","year":"2021","unstructured":"Moghetti P, Tosi F. Insulin resistance and PCOS:chicken or egg? J Endocrinol Invest. 2021;44(2):233\u201344. https:\/\/doi.org\/10.1007\/s40618-020-01351-0.","journal-title":"J Endocrinol Invest"},{"key":"5944_CR41","doi-asserted-by":"publisher","first-page":"1003238","DOI":"10.3389\/fendo.2022.1003238","volume":"13","author":"J Zhang","year":"2022","unstructured":"Zhang J, Xing C, Cheng X, He B. Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome:a single-center,open-labeled prospective randomized controlled trial. Front Endocrinol (Lausanne). 2022;13:1003238.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"5944_CR42","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1093\/humrep\/deab181","volume":"36","author":"S Palomba","year":"2021","unstructured":"Palomba S. Is fertility reduced in ovulatory women with polycystic ovary syndrome an opinion paper. Hum Reprod. 2021;36(9):2421\u20138.","journal-title":"Hum Reprod"},{"issue":"2","key":"5944_CR43","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/cen.14723","volume":"97","author":"M Bahri Khomami","year":"2022","unstructured":"Bahri Khomami M, Teede HJ, Joham AE, Moran LJ, Piltonen TT, Boyle JA. Clinical management of pregnancy in women with polycystic ovary syndrome: an expert opinion. Clin endocrinol. (Oxf). 2022;97(2):227\u201336. https:\/\/doi.org\/10.1111\/cen.14723.","journal-title":"(Oxf)"},{"key":"5944_CR44","doi-asserted-by":"publisher","unstructured":"Palomba S. Is fertility reduced in ovulatory women with polycystic ovary syndrome? An opinion paper. Hum reprod. 2021;36(9):2421\u20138. https:\/\/doi.org\/10.1093\/humrep\/deab181.","DOI":"10.1093\/humrep\/deab181"},{"issue":"3","key":"5944_CR45","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/humupd\/dmaa051","volume":"27","author":"S Palomba","year":"2021","unstructured":"Palomba S, Piltonen TT, Giudice LC. Endometrial function in women with polycystic ovary syndrome: a comprehensive review. Hum Reprod Update. 2021;27(3):584\u2013618.","journal-title":"Hum Reprod Update"},{"key":"5944_CR46","doi-asserted-by":"publisher","unstructured":"Shetty C, Rizvi SMHA, Sharaf J et al. Risk of Gynecological Cancers in Women with Polycystic Ovary Syndrome and the pathophysiology of Association.Cureus. 2023;15(4):e37266. Published 2023 Apr 7. https:\/\/doi.org\/10.7759\/cureus.37266.","DOI":"10.7759\/cureus.37266"},{"issue":"4","key":"5944_CR47","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3892\/ol.2023.13754","volume":"25","author":"JE Johnson","year":"2023","unstructured":"Johnson JE, Daley D, Tarta C, Stanciu PI. Risk of endometrial cancer in patients with polycystic ovarian syndrome:a metaanalysis. Oncol Lett. 2023;25(4):168. https:\/\/doi.org\/10.3892\/ol.2023.13754. Published 2023 Mar 8.","journal-title":"Oncol Lett"},{"key":"5944_CR48","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3389\/fphar.2022.904942","volume":"13","author":"H Shan","year":"2022","unstructured":"Shan H, Luo R, Guo X, et al. Abnormal endometrial receptivity and oxidative stress in polycystic ovary syndrome. Front Pharmacol. 2022;13:904\u201342.","journal-title":"Front Pharmacol"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-023-05944-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-023-05944-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-023-05944-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T21:48:25Z","timestamp":1700344105000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-023-05944-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["5944"],"URL":"https:\/\/doi.org\/10.1186\/s12884-023-05944-4","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"assertion":[{"value":"31 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was provided by the Reproductive Ethics Committee of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine. All experiments were performed in accordance with relevant guidelines and regulations (such as the Declaration of Helsinki). The participants provided their written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"618"}}